Özcan Kazim Serhan, Osmonov Damirbek, Toprak Ercan, Güngör Barış, Tatlısu Adem, Ekmekçi Ahmet, Kaya Adnan, Tayyareci Gülşah, Erdinler İzzet
Almaty Sema Hospital, Almaty, Kazakhstan.
Cardiol J. 2014;21(3):238-44. doi: 10.5603/CJ.a2013.0108. Epub 2013 Aug 30.
Concomitant thyroid and heart disease are frequently encountered in clinical practice. There are many studies evaluating thyroid function in acute and critical conditions. Information on thyroid dysfunction in ST-segment elevation myocardial infarction (STEMI) is limited; its correlation with short and long-term outcome is not fully known.
Four hundred and fifty seven patients diagnosed with STEMI in our emergency department were included in the study. Patients were divided into two groups: patients with normal thyroid function (euthyroid) and patients with thyroid dysfunction. STEMI was diagnosed with 12 derivation surface electrocardiogram. Thyroid hormone levels (TSH, free T3 and free T4) were measured. Patients with other acute coronary syndromes and endocrine pathologies except diabetes mellitus were excluded. Two patient groups were compared in terms of in-hospital and long-term outcome.
Out of 457, 72 (15%) patients with thyroid dysfunction were detected. The other patients were euthyroid and constituted the control group. In-hospital cardiogenic shock (15% vs. 3% in the control group; p < 0.01) and death (7% vs. 1% in the control group; p < 0.01) were more frequently observed in the thyroid dysfunction group. In the subgroup analysis, it was observed that patients with sick euthyroid syndrome have the poorest outcome. Other markers for poor outcome were anemia and renal failure.
Thyroid dysfunction, particularly sick euthyroid syndrome, was found to be related to in-hospital and long term mortality in patients with STEMI undergoing primary percutaneous intervention.
甲状腺疾病与心脏疾病在临床实践中经常同时出现。有许多研究评估了急性和危重症情况下的甲状腺功能。关于ST段抬高型心肌梗死(STEMI)患者甲状腺功能障碍的信息有限;其与短期和长期预后的相关性尚不完全清楚。
本研究纳入了在我院急诊科诊断为STEMI的457例患者。患者分为两组:甲状腺功能正常(甲功正常)组和甲状腺功能障碍组。通过12导联体表心电图诊断STEMI。检测甲状腺激素水平(促甲状腺激素、游离三碘甲状腺原氨酸和游离甲状腺素)。排除患有其他急性冠状动脉综合征和除糖尿病外的内分泌疾病的患者。比较两组患者的院内和长期预后。
457例患者中,检测到72例(15%)甲状腺功能障碍患者。其他患者甲功正常,构成对照组。甲状腺功能障碍组院内心源性休克(15% vs对照组3%;p<0.01)和死亡(7% vs对照组1%;p<0.01)的发生率更高。在亚组分析中,观察到低T3综合征患者的预后最差。其他预后不良的指标是贫血和肾衰竭。
在接受直接经皮冠状动脉介入治疗的STEMI患者中,甲状腺功能障碍,尤其是低T3综合征,与院内和长期死亡率相关。